logo
Share SHARE
FONT-SIZE Plus   Neg

ZIOPHARM Oncology COO Richard Bagley Steps Down

Biopharmaceutical company ZIOPHARM Oncology, Inc. (ZIOP: Quote) said Monday that the company's President, Chief Operating Officer and Director Richard Bagley is leaving the company and stepping down from the company's board of Directors.

The company also noted that Mark Thornton, Executive Vice President, Government Affairs, Health Policy and Advocacy and Chief Quality Compliance Officer, is also leaving ZIOPHARM to pursue other opportunities.

The company said that the President of Research and Development and Chief Medical Officer, Hagop Youssoufian, will assume the additional responsibility of oversight of all regulatory affairs and clinical operations. Also Caesar Belbel, Executive Vice President, Chief Legal Officer and Secretary, will shoulder the additional responsibility for corporate and business development.

The company also noted that Jason Amello, Executive Vice President and Chief Financial Officer, will continue to be responsible for finance and information technology, and Lynn Ferrucci, Senior Vice President, Human Resources, will continue to oversee human resources.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
If calories are not reduced, exercise alone can have no effect on obesity, says British Sports Medicine, a peer-reviewed journal of sport and exercise medicine. The journal says the blame for expanding waist lines is directly on the type and amount of calories consumed and the poor diet generates more disease than physical inactivity, alcohol and smoking combined. Deutsche Bank (DB) on Sunday reported an about 50 percent decline in first-quarter profit, despite clocking double-digit revenue growth, as the German lender recorded hefty legal charges over allegations of rate-rigging. Casino operator Wynn Resorts said its shareholders ousted Elaine Wynn from the board, reflecting fears that her presence may lead to disharmony with the management.
comments powered by Disqus
Follow RTT